Characteristic | Unadjusted cohort* | IPTW-adjusted cohort† | ||||
PLD (n=198) | SLN biopsy (n=188) | p value‡ | PLD (n=198) | SLN biopsy (n=188) | p value‡ | |
Any intra-operative complication | 4 (2.0) | 1 (0.5) | 0.23 | 2.0% | 0.4% | 0.19 |
Conversion to open operation§ | 2 (1.0) | 1 (0.5) | 0.60 | 1.0% | 0.8% | 0.83 |
Post-operative complications within 30 days | ||||||
ASC grade ≥2 | 15 (7.6) | 9 (4.8) | 0.26 | 6.3% | 4.7% | 0.50 |
ASC grade ≥3 | 3 (1.5) | 1 (0.5) | 0.36 | 1.2% | 0.5% | 0.49 |
Re-admission within 30 days | 7 (3.5) | 4 (2.1) | 0.41 | 2.7% | 1.9% | 0.61 |
Re-operation within 30 days | 2 (1.0) | 0.0 (0.0) | 0.31 | 0.8% | 0.0 (0.0) | 0.39 |
Operative time, mean (SD), min | 225.3 (71.4) | 136.6 (42.0) | <0.001 | 222.8 (70.1) | 138.0 (44.0) | <0.001 |
EBL, median (IQR), mL | 100 (60–200) | 50 (50–100) | <0.001 | 100 (50–200) | 50 (50–100) | <0.001 |
Length of hospital stay, days | ||||||
≥2 | 46 (23.2) | 15 (8.0) | <0.001 | 21.6% | 7.8% | <0.001 |
≥3 | 14 (7.1) | 9 (4.8) | 0.35 | 6.9% | 4.9% | 0.40 |
Length of hospital stay after ERAS protocol implementation, days | ||||||
≥2 | 23/119 (19.3) | 15/188 (8.0) | 0.004 | 19.2% | 7.8% | 0.004 |
≥3 | 6/119 (5.0) | 9/188 (4.8) | 0.92 | 5.5% | 4.9% | 0.82 |
*Results are reported as number (%) of patients unless stated otherwise.
†Results are reported as weighted mean (SD), weighted median (IQR), or weighted percentage.
‡Comparisons between groups were evaluated with a logistic regression model for binary outcomes and a linear regression model for continuous outcomes. EBL was analyzed after application of a logarithmic transformation.
§Conversions to open operation in the PLD group were for staging. The only conversion in the SLN group was for hysterectomy.
ASC, Accordion Severity Classification; EBL, estimated blood loss; ERAS, Enhanced Recovery After Surgery; IPTW, inverse probability of treatment weighting; IQR, interquartile range; PLD, pelvic lymphadenectomy; SLN, sentinel lymph node.